Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $2.5 million.

  • Heron Therapeutics' Depreciation & Amortization (CF) rose 5.85% to $615,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 9.94%. This contributed to the annual value of $2.5 million for FY2024, which is 13.79% down from last year.
  • Heron Therapeutics' Depreciation & Amortization (CF) amounted to $2.5 million in FY2024, which was down 13.79% from $2.9 million recorded in FY2023.
  • Heron Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $3.0 million for FY2021, and its period low was $2.5 million during FY2024.
  • Its 3-year average for Depreciation & Amortization (CF) is $2.8 million, with a median of $2.9 million in 2022.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first spiked by 39.29% in 2020, then decreased by 13.79% in 2024.
  • Over the past 5 years, Heron Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $2.8 million in 2020, then rose by 6.11% to $3.0 million in 2021, then declined by 4.37% to $2.9 million in 2022, then climbed by 0.38% to $2.9 million in 2023, then fell by 13.79% to $2.5 million in 2024.